Nucleonics Takes Benitec Dispute to Europe; Opposition to Alnylam Patent Moves Forward | GenomeWeb

Nucleonics said this week that it has taken its intellectual property battle with Benitec to Europe, filing with the EPO examples of prior art that the company says demonstrate why Benitec should not be awarded a European patent covering its core RNAi technology.

According to Nucleonics, the prior art citations provided to the EPO are relevant to Benitec’s patent application number 1071762, entitled “Control of Gene Expression.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.